Compare GCV & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GCV | MDXH |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | 312 |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.1M | 167.8M |
| IPO Year | N/A | 2021 |
| Metric | GCV | MDXH |
|---|---|---|
| Price | $4.16 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 57.9K | ★ 177.1K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 13.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $3.15 | $1.35 |
| 52 Week High | $4.58 | $5.33 |
| Indicator | GCV | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 34.99 |
| Support Level | $4.23 | $3.31 |
| Resistance Level | $4.30 | $3.74 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 15.00 | 8.65 |
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.